Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway

Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the most promising micro-cap stocks according to analysts. On February 18, Spruce Biosciences recently concluded successful Type B meetings with the FDA, clearing a path for the BLA submission of tralesinidase alfa enzyme replacement therapy (TA-ERT). The Agency confirmed that existing clinical and natural history data could support an accelerated approval based on the reduction of heparan sulfate non-reducing end (HS-NRE) in cerebral spinal fluid.

This biomarker is considered a reasonably likely surrogate endpoint, as Spruce showed that lowering these toxic levels is associated with meaningful improvements in cognition and motor skills for patients with Sanfilippo Syndrome Type B (MPS IIIB). To meet the FDA’s Chemistry, Manufacturing, and Controls requirements, Spruce adjusted its BLA submission timeline to Q4 2026. This shift allows the company to complete the necessary process performance qualification batches for the drug product.

Additionally, Spruce Biosciences Inc. (NASDAQ:SPRB) reached an agreement with the Agency to initiate a required confirmatory study while the BLA is under review. This ensures that the manufacturing and clinical data packages meet the rigorous standards necessary for potentially the first disease-modifying treatment for this fatal genetic disorder. The regulatory outlook for TA-ERT is further supported by its status as a recipient of Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations.

Spruce Biosciences Inc. (NASDAQ:SPRB) is a biopharmaceutical company that develops and commercializes novel therapies for neurological disorders.